These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 18954262)

  • 1. Peroxisome proliferator-activated receptor gamma agonists and the treatment of HIV-associated lipoatrophy: unraveling the molecular mechanism of their shortcomings.
    Hadigan C
    J Infect Dis; 2008 Dec; 198(12):1729-31. PubMed ID: 18954262
    [No Abstract]   [Full Text] [Related]  

  • 2. HIV-associated lipoatrophy: what are the kinder, gentler agents?
    Dubé MP
    Clin Infect Dis; 2006 Jan; 42(2):281-2. PubMed ID: 16355342
    [No Abstract]   [Full Text] [Related]  

  • 3. Pathogenesis and treatment of lipodystrophy: what clinicians need to know.
    Sattler FR
    Top HIV Med; 2008; 16(4):127-33. PubMed ID: 18838747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival.
    Davidson B; Hadar R; Stavnes HT; Trope' CG; Reich R
    Hum Pathol; 2009 May; 40(5):705-13. PubMed ID: 19157507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV lipodystrophy: where are we after ten years?
    Vergel N
    GMHC Treat Issues; 2007; 21(3-4):10-5. PubMed ID: 19230305
    [No Abstract]   [Full Text] [Related]  

  • 6. HIV and insulin resistance in context.
    Kotler DP
    AIDS Read; 2005 May; 15(5):220. PubMed ID: 15900630
    [No Abstract]   [Full Text] [Related]  

  • 7. What does the term "HIV-associated lipodystrophy" mean?
    Marcason W
    J Am Diet Assoc; 2009 Feb; 109(2):364. PubMed ID: 19167963
    [No Abstract]   [Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptor-gamma agonists promote differentiation and antioxidant defenses of oligodendrocyte progenitor cells.
    Bernardo A; Bianchi D; Magnaghi V; Minghetti L
    J Neuropathol Exp Neurol; 2009 Jul; 68(7):797-808. PubMed ID: 19535992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenesis and management of lipoatrophy.
    Tungsiripat M; McComsey G
    Curr HIV/AIDS Rep; 2008 May; 5(2):55-63. PubMed ID: 18510890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy.
    Sievers M; Walker UA; Sevastianova K; Setzer B; Wågsäter D; Eriksson P; Yki-Järvinen H; Sutinen J
    J Infect Dis; 2009 Jul; 200(2):252-62. PubMed ID: 19519254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Stigmatization, metabolic trouble, drug resistance: current challenges in HIV therapy].
    Mauss S; Jablonowski H
    MMW Fortschr Med; 2009 Apr; 151(18):28. PubMed ID: 19769068
    [No Abstract]   [Full Text] [Related]  

  • 12. Managing HIV lipoatrophy.
    Moyle G; Sutinen J
    Lancet; 2004 Feb; 363(9407):412-4. PubMed ID: 14962517
    [No Abstract]   [Full Text] [Related]  

  • 13. Peroxisome proliferator-activated receptor gamma agonists in kidney disease--future promise, present fears.
    Mao Z; Ong AC
    Nephron Clin Pract; 2009; 112(4):c230-41. PubMed ID: 19546582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disorders of body fat distribution in HIV-1-infected patients.
    Moreno S; Miralles C; Negredo E; Domingo P; Estrada V; Gutiérrez F; Lozano F; Martínez E
    AIDS Rev; 2009; 11(3):126-34. PubMed ID: 19654854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stavudine in antiretroviral therapy: is this the end?
    Brinkman K
    AIDS; 2009 Aug; 23(13):1727-9. PubMed ID: 19571724
    [No Abstract]   [Full Text] [Related]  

  • 16. Protective effect of peroxisome proliferator-activated receptor-gamma agonists on activated renal proximal tubular epithelial cells in IgA nephropathy.
    Xiao J; Leung JC; Chan LY; Guo H; Lai KN
    Nephrol Dial Transplant; 2009 Jul; 24(7):2067-77. PubMed ID: 19155534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced beta-catenin and peroxisome proliferator-activated receptor-gamma expression levels are associated with colorectal cancer metastatic progression: correlation with tumor-associated macrophages, cyclooxygenase 2, and patient outcome.
    Pancione M; Forte N; Sabatino L; Tomaselli E; Parente D; Febbraro A; Colantuoni V
    Hum Pathol; 2009 May; 40(5):714-25. PubMed ID: 19121846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Side effects of antiretroviral therapy--skin manifestations].
    Esser S
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():8, 10-1. PubMed ID: 19024907
    [No Abstract]   [Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptor gamma is constitutively activated in yeast.
    Mueller M; Jungbauer A
    Anal Biochem; 2009 Feb; 385(2):365-7. PubMed ID: 19032928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical management of HIV-associated lipodystrophy.
    Pirmohamed M
    Curr Opin Lipidol; 2009 Aug; 20(4):309-14. PubMed ID: 19494771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.